309 related articles for article (PubMed ID: 28202511)
21. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
[TBL] [Abstract][Full Text] [Related]
22. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy.
Liao BC; Lin CC; Lee JH; Yang JC
Lung Cancer; 2017 Aug; 110():7-13. PubMed ID: 28676222
[TBL] [Abstract][Full Text] [Related]
23. Effect of dasatinib on EMT-mediated-mechanism of resistance against EGFR inhibitors in lung cancer cells.
Sesumi Y; Suda K; Mizuuchi H; Kobayashi Y; Sato K; Chiba M; Shimoji M; Tomizawa K; Takemoto T; Mitsudomi T
Lung Cancer; 2017 Feb; 104():85-90. PubMed ID: 28213007
[TBL] [Abstract][Full Text] [Related]
24. Managing acquired resistance in EGFR-mutated non-small cell lung cancer.
Forde PM; Ettinger DS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):528-32. PubMed ID: 26351816
[TBL] [Abstract][Full Text] [Related]
25. Paxillin confers resistance to tyrosine kinase inhibitors in EGFR-mutant lung cancers via modulating BIM and Mcl-1 protein stability.
Wu DW; Chen CY; Chu CL; Lee H
Oncogene; 2016 Feb; 35(5):621-30. PubMed ID: 25915848
[TBL] [Abstract][Full Text] [Related]
26. Acquired resistance of non-small cell lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors.
Nurwidya F; Takahashi F; Murakami A; Kobayashi I; Kato M; Shukuya T; Tajima K; Shimada N; Takahashi K
Respir Investig; 2014 Mar; 52(2):82-91. PubMed ID: 24636263
[TBL] [Abstract][Full Text] [Related]
27. The combination of irreversible EGFR TKIs and SAHA induces apoptosis and autophagy-mediated cell death to overcome acquired resistance in EGFR T790M-mutated lung cancer.
Lee TG; Jeong EH; Kim SY; Kim HR; Kim CH
Int J Cancer; 2015 Jun; 136(11):2717-29. PubMed ID: 25382705
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic strategy for advanced EGFR mutant non-small-cell lung carcinoma.
Cadranel J; Ruppert AM; Beau-Faller M; Wislez M
Crit Rev Oncol Hematol; 2013 Dec; 88(3):477-93. PubMed ID: 23911281
[TBL] [Abstract][Full Text] [Related]
29. [Precision treatment after resistance to first-generation EGFR-TKI in patients with non-small cell lung cancer].
Pi C; Zhang YC; Xu CR; Zhou Q
Zhonghua Zhong Liu Za Zhi; 2017 Feb; 39(2):94-97. PubMed ID: 28219202
[TBL] [Abstract][Full Text] [Related]
30. Gallic acid inhibition of Src-Stat3 signaling overcomes acquired resistance to EGF receptor tyrosine kinase inhibitors in advanced non-small cell lung cancer.
Phan AN; Hua TN; Kim MK; Vo VT; Choi JW; Kim HW; Rho JK; Kim KW; Jeong Y
Oncotarget; 2016 Aug; 7(34):54702-54713. PubMed ID: 27419630
[TBL] [Abstract][Full Text] [Related]
31. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
[TBL] [Abstract][Full Text] [Related]
32. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, sensitizes lung cancer cells to treatment with epidermal growth factor receptor tyrosine kinase inhibitors.
Liu M; Xu S; Wang Y; Li Y; Li Y; Zhang H; Liu H; Chen J
Oncotarget; 2016 Dec; 7(51):84951-84964. PubMed ID: 27825114
[TBL] [Abstract][Full Text] [Related]
33. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer.
Ayeni D; Politi K; Goldberg SB
Clin Cancer Res; 2015 Sep; 21(17):3818-20. PubMed ID: 26169963
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor β1 activation accelerates resistance to epidermal growth factor receptor-tyrosine kinase inhibitors in non-small cell lung cancer.
Fu S; Liu C; Huang Q; Fan S; Tang H; Fu X; Ai B; Liao Y; Chu Q
Oncol Rep; 2018 Mar; 39(3):1313-1321. PubMed ID: 29328407
[TBL] [Abstract][Full Text] [Related]
35. Dacomitinib in lung cancer: a "lost generation" EGFR tyrosine-kinase inhibitor from a bygone era?
Ou SH; Soo RA
Drug Des Devel Ther; 2015; 9():5641-53. PubMed ID: 26508839
[TBL] [Abstract][Full Text] [Related]
36. Acquired
Li A; Yang JJ; Zhang XC; Zhang Z; Su J; Gou LY; Bai Y; Zhou Q; Yang Z; Han-Zhang H; Zhong WZ; Chuai S; Zhang Q; Xie Z; Gao H; Chen H; Wang Z; Wang Z; Yang XN; Wang BC; Gan B; Chen ZH; Jiang BY; Wu SP; Liu SY; Xu CR; Wu YL
Clin Cancer Res; 2017 Aug; 23(16):4929-4937. PubMed ID: 28396313
[No Abstract] [Full Text] [Related]
37. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer.
Engelman JA; Mukohara T; Zejnullahu K; Lifshits E; Borrás AM; Gale CM; Naumov GN; Yeap BY; Jarrell E; Sun J; Tracy S; Zhao X; Heymach JV; Johnson BE; Cantley LC; Jänne PA
J Clin Invest; 2006 Oct; 116(10):2695-706. PubMed ID: 16906227
[TBL] [Abstract][Full Text] [Related]
38. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
39. Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.
Klempner SJ; Bazhenova LA; Braiteh FS; Nikolinakos PG; Gowen K; Cervantes CM; Chmielecki J; Greenbowe JR; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
Lung Cancer; 2015 Sep; 89(3):357-9. PubMed ID: 26187428
[TBL] [Abstract][Full Text] [Related]
40. Celastrol improves the therapeutic efficacy of EGFR-TKIs for non-small-cell lung cancer by overcoming EGFR T790M drug resistance.
Wang Y; Liu Q; Chen H; You J; Peng B; Cao F; Zhang X; Chen Q; Uzan G; Xu L; Zhang D
Anticancer Drugs; 2018 Sep; 29(8):748-755. PubMed ID: 29927769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
